EA200101089A1 - Новый способ лечения - Google Patents

Новый способ лечения

Info

Publication number
EA200101089A1
EA200101089A1 EA200101089A EA200101089A EA200101089A1 EA 200101089 A1 EA200101089 A1 EA 200101089A1 EA 200101089 A EA200101089 A EA 200101089A EA 200101089 A EA200101089 A EA 200101089A EA 200101089 A1 EA200101089 A1 EA 200101089A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
new method
neutrophils
mammal
toxic
Prior art date
Application number
EA200101089A
Other languages
English (en)
Inventor
Колин Хаустон Макфи
Original Assignee
Смитклайн Бичам Плс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Смитклайн Бичам Плс filed Critical Смитклайн Бичам Плс
Publication of EA200101089A1 publication Critical patent/EA200101089A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11B—INFORMATION STORAGE BASED ON RELATIVE MOVEMENT BETWEEN RECORD CARRIER AND TRANSDUCER
    • G11B20/00—Signal processing not specific to the method of recording or reproducing; Circuits therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Signal Processing (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

Способ лечения заболевания или состояния, связанного с повышенными количествами нейтрофилов и/или чрезмерной активацией нейтрофилов у млекопитающего, такого как человек; указанный способ включает введение эффективного, нетоксичного и фармацевтически приемлемого количества агониста PPARγ, такого как соединение (I), млекопитающему, которое нуждается в указанном лечении.
EA200101089A 1999-04-15 2000-04-17 Новый способ лечения EA200101089A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9908647.2A GB9908647D0 (en) 1999-04-15 1999-04-15 Novel compounds
PCT/GB2000/001499 WO2000062766A2 (en) 1999-04-15 2000-04-17 Uses of ppar-gamma agonists in neutrophil-induced diseases

Publications (1)

Publication Number Publication Date
EA200101089A1 true EA200101089A1 (ru) 2002-10-31

Family

ID=10851605

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200101089A EA200101089A1 (ru) 1999-04-15 2000-04-17 Новый способ лечения

Country Status (32)

Country Link
EP (2) EP1274407B1 (ru)
JP (1) JP2003516310A (ru)
KR (1) KR20010108506A (ru)
CN (1) CN1413105A (ru)
AP (1) AP2001002291A0 (ru)
AT (1) ATE319437T1 (ru)
AU (1) AU4583000A (ru)
BG (1) BG106104A (ru)
BR (1) BR0009776A (ru)
CA (1) CA2370127A1 (ru)
CZ (1) CZ20013688A3 (ru)
DE (1) DE60026508T2 (ru)
DK (1) DK1274407T3 (ru)
DZ (1) DZ3151A1 (ru)
EA (1) EA200101089A1 (ru)
ES (1) ES2256003T3 (ru)
GB (1) GB9908647D0 (ru)
HK (1) HK1053788A1 (ru)
HR (1) HRP20010746A2 (ru)
HU (1) HUP0300479A2 (ru)
ID (1) ID30339A (ru)
IL (1) IL145875A0 (ru)
MA (1) MA25351A1 (ru)
MX (1) MXPA01010428A (ru)
NO (1) NO20014950L (ru)
PL (1) PL364720A1 (ru)
PT (1) PT1274407E (ru)
SK (1) SK14532001A3 (ru)
TR (1) TR200102977T2 (ru)
WO (1) WO2000062766A2 (ru)
YU (1) YU77901A (ru)
ZA (1) ZA200108446B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2742417C1 (ru) * 2017-01-13 2021-02-05 Тобиси Фармасьютикал Ко., Лтд. Регулятор активации нейтрофилов

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9913782D0 (en) * 1999-06-14 1999-08-11 Smithkline Beecham Plc Novel compounds
WO2002038150A1 (de) * 2000-11-09 2002-05-16 Phenion Gmbh & Co. Kg Aktivatoren von peroxisom-proliferator-aktivierten rezeptoren alpha, beta als arzneimittel zur behandlung von immunologisch bedingten hautstörungen
GB0030845D0 (en) * 2000-12-18 2001-01-31 Smithkline Beecham Plc Novel treatment
GB2373725A (en) * 2001-03-30 2002-10-02 Novartis Ag Use of a PPAR gamma agonist in the production of a medicament for the prevention or treatment of diseases associated with IL-10 production
JP2005513031A (ja) * 2001-11-26 2005-05-12 アラクノーバ・セラピューティックス・リミテッド 肺線維症の処置のためのｐｐａｒアクチベーターの使用
DE10204398A1 (de) * 2002-02-04 2003-08-14 Univ Goettingen Georg August Neue Verwendung von Liganden der 'Peroxisome Proliferator-Activated receptors'(PPAR)
US6992093B2 (en) 2002-05-02 2006-01-31 Los Angeles Biomedical Research Institute At Harbor Ucla Medical Center Method of inhibiting lipofibroblast to myofibroblast transdifferentiation
US8293479B2 (en) 2002-05-02 2012-10-23 Los Angeles Biomedical Research Institute At Harbor Ucla Medical Center Use of parathyroid hormone-related protein(PTHRP) in the diagnosis and treatment of chronic lung disease and other pathologies
US20030220300A1 (en) * 2002-05-14 2003-11-27 Hwang Cheng Shine Reduction of hair growth
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
KR101333089B1 (ko) 2006-05-22 2013-11-27 재단법인 아산사회복지재단 로지글리타존을 유효성분으로 함유하는 흡연-유발 만성폐쇄성 폐질환 예방 또는 치료용 약제학적 조성물
GB0913672D0 (en) 2009-08-05 2009-09-16 Argenta Discovery Ltd Glitazones
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
CA2733440C (en) * 2008-08-07 2016-06-28 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
WO2010076553A1 (en) 2008-12-30 2010-07-08 Dr. Reddy's Laboratories Ltd Sulfonamide compounds for the treatment of respiratory disorders
WO2010091892A2 (en) 2009-02-16 2010-08-19 Giuliani International Limited Alkylamido compounds and uses thereof
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
JP6301844B2 (ja) 2012-02-09 2018-03-28 ノグラ ファーマ リミテッド 線維症の処置方法
CN104284655B (zh) 2012-04-18 2017-10-27 诺格拉制药有限公司 治疗乳糖不耐受的方法
WO2016040313A2 (en) * 2014-09-08 2016-03-17 Dana-Farber Cancer Institute, Inc. Methods of treating cancer
CN113825739A (zh) 2019-02-08 2021-12-21 诺格拉制药有限公司 制备3-(4’-氨基苯基)-2-甲氧基丙酸及其类似物和中间体的方法
JP2020145939A (ja) * 2019-03-12 2020-09-17 日本製粉株式会社 アレルギー性鼻炎抑制用組成物
CN116531374A (zh) * 2023-04-20 2023-08-04 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 吡格列酮及其盐在制备用于治疗系统性红斑狼疮的产品中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9611947D0 (en) * 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments
JPH10139665A (ja) * 1996-09-12 1998-05-26 Sankyo Co Ltd トログリタゾンを含有するグルタチオン還元酵素活性増強剤
ATE253903T1 (de) * 1996-12-11 2003-11-15 Dana Farber Cancer Inst Inc Methoden und pharmazeutische zusammenstellungen zur wachstumsverhinderung von tumorzellen enthaltend einen ppar-gamma agonisten und einen map kinase inhibitor
CA2276288A1 (en) * 1996-12-31 1998-07-09 Laszlo Nagy Treatment of disease states which result from neoplastic cell proliferation using ppar-gamma activators and compositions useful therefor
FR2773075B1 (fr) * 1997-12-31 2000-05-05 Cird Galderma Utilisation d'activateurs de ppar-gamma en dermatologie
US6028088A (en) * 1998-10-30 2000-02-22 The University Of Mississippi Flavonoid derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2742417C1 (ru) * 2017-01-13 2021-02-05 Тобиси Фармасьютикал Ко., Лтд. Регулятор активации нейтрофилов

Also Published As

Publication number Publication date
PT1274407E (pt) 2006-06-30
WO2000062766A2 (en) 2000-10-26
TR200102977T2 (tr) 2002-09-23
EP1274407B1 (en) 2006-03-08
EP1593379A3 (en) 2007-10-31
EP1593379A2 (en) 2005-11-09
GB9908647D0 (en) 1999-06-09
DZ3151A1 (fr) 2000-10-19
DE60026508D1 (de) 2006-05-04
CA2370127A1 (en) 2000-10-26
AU4583000A (en) 2000-11-02
DE60026508T2 (de) 2006-11-16
ZA200108446B (en) 2003-08-27
MA25351A1 (fr) 2001-12-31
ATE319437T1 (de) 2006-03-15
SK14532001A3 (sk) 2002-02-05
YU77901A (sh) 2005-07-19
NO20014950L (no) 2001-12-13
HRP20010746A2 (en) 2002-10-31
NO20014950D0 (no) 2001-10-11
HK1053788A1 (zh) 2003-11-07
DK1274407T3 (da) 2006-06-26
AP2001002291A0 (en) 2001-12-31
WO2000062766A3 (en) 2002-10-31
BR0009776A (pt) 2002-06-04
HUP0300479A2 (hu) 2003-07-28
KR20010108506A (ko) 2001-12-07
ES2256003T3 (es) 2006-07-16
IL145875A0 (en) 2002-07-25
CZ20013688A3 (cs) 2003-03-12
CN1413105A (zh) 2003-04-23
EP1274407A2 (en) 2003-01-15
BG106104A (en) 2002-05-31
PL364720A1 (en) 2004-12-13
MXPA01010428A (es) 2002-05-06
JP2003516310A (ja) 2003-05-13
ID30339A (id) 2001-11-22

Similar Documents

Publication Publication Date Title
EA200101089A1 (ru) Новый способ лечения
EA199800626A1 (ru) Применение агониста ppar-гамма для лечения синдрома х
BR0111800A (pt) Combinações de inibidores de depeptidil peptidase iv e outros agentes antidiabéticos para o tratamento de diabete mellitus
LU91926I2 (fr) Belimumab et ses dérivés pharmaceutiquement acceptables (Benlysta®)
EA200001044A3 (ru) Соединения для лечения женской сексуальной дисфункции
TW200505900A (en) Muscarinic agonists
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
BR0108977A (pt) Compostos azacìclicos para uso no tratamento de doenças relaciondas com serotonina
DK0880350T3 (da) Behandling af dissemineret sklerose
BRPI0411677A (pt) métodos de uso de compostos heterocìclicos [3.2.0] e seus análogos
PT867178E (pt) Utilizacao de agonistas nao alostericos de gaba para o tratamento de desordens do sono
AP2001002129A0 (en) 5HT1 receptor agonists and metoclopramide for the treatment of migrane.
DE60031714D1 (de) Thrombopoietin-mimetika
BR9808221A (pt) Método de tratamento de tumor.
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
EA200000042A1 (ru) Способ лечения диабета росиглитазоном и инсулином
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
TR200101336T2 (tr) Bir-beta-agonisti ile başka bir antidiyabetik madde içeren kombinasyonlar
ATE347364T1 (de) Quetiapin zur behandlung der dyskinesie in nicht- psychotischen patienten
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
TR200000957T2 (tr) Hiperglisemi tedavisinde tiazolidinedion kullanımı
MX9700626A (es) USO DE AZASPIRANOS EN LA REPARACIaN DE COMPOSICIONES PARA TRATAR INFECCIONES OPORTUNISTAS.
EA200000419A1 (ru) Применение тиазолидиндионов для лечения гипергликемии
MX9701533A (es) Procedimiento para reducir lesiones en tejidos asociadas con isquemia no cardiaca.
WO2002076405A3 (en) Compositions and methods of treatment of ulcerating diseases, burns, and related conditions